Featured News
AMPEL BioSolutions Enters MDx Market With Lupus, Dermatology Gene Expression Assays
AMPEL BioSolutions’ Machine Learning Breakthrough Predicts Drug Options for Inflammatory Skin Diseases
New test may guide treatment of common skin diseases
DERMATOLOGY NEWS
AMPEL BioSolutions Enters MDx Market With Lupus, Dermatology Gene Expression Assays
After nine years in business, precision medicine company AMPEL BioSolutions is broadening its market from pharmaceutical companies to healthcare providers and their patients.
AMPEL BioSolutions’ Machine Learning Breakthrough Predicts Drug Options for Inflammatory Skin Diseases
AMPEL BioSolutions announced a breakthrough in precision and personalized medicine that could revolutionize the way doctors treat inflammatory skin diseases, such as Lupus, Psoriasis, Atopic Dermatitis and Scleroderma.
Ready for Prime Time? Ampel’s Blood Tests May Predict Drug Options for Inflammatory Skin Disease
Products expected to launch in 2022-2023 include LuGENE, a blood test for Lupus, and DermaGENE a skin biopsy test for lupus, psoriasis, atopic dermatitis, and scleroderma.
New test may guide treatment of common skin diseases
Dermatologists routinely do skin biopsies to figure out what’s wrong with their patients. They study tissue under a microscope – looking at the structure of cells, but a Charlottesville company says doctors could treat disease more precisely by looking at genetics.
Virginia Based AMPEL BioSolutions’ Machine Learning Breakthrough Predicts Drug Options for Inflammatory Skin Diseases
AMPEL BioSolutions announces a breakthrough in precision and personalized medicine that could revolutionize the way doctors treat inflammatory skin diseases, such as Lupus, Psoriasis, Atopic Dermatitis and Scleroderma.